美国 · SEC FORM 4
Lexeo Therapeutics, Inc.
LXEO · Nasdaq · CIK 0001907108 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
16 同一窗口内观察到的 Form 4 交易行
9 sales · 7 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-11-25 · CHOLMONDELEY PAULA H.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 19,246,976
- 上期报告
- 20,627,916
- 日均成交量
- 2,129,601
- 回补天数
- 9.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-11-25 | CHOLMONDELEY PAULA H | 买入 (P) | Common Stock | 15,000 | USD 6.99 | USD 104,850 | SEC 申报 ↗ |
| 2023-11-07 | Nessi Claudio; Omega Fund VI GP Manager, Ltd.; Omega Fund VI GP, L.P.; Omega Fund VI, L.P.; Paster Anne-Mari; Stampacchia Otello | 买入 (P) | Common Stock | 454,545 | USD 11.00 | USD 4,999,995 | SEC 申报 ↗ |
| 2023-11-07 | Lundbeckfond Invest A/S | 买入 (P) | Common Stock | 227,272 | USD 11.00 | USD 2,499,992 | SEC 申报 ↗ |
| 2023-11-07 | ENRIGHT PATRICK G; Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.; Tammenoms Bakker Juliet | 买入 (P) | Common Stock | 454,545 | USD 11.00 | USD 4,999,995 | SEC 申报 ↗ |
Form 4 申报证据
30 transaction lines in the latest 365-day window; 107 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Townsend Richard Nolan | 奖励/授予 (A) | Common Stock | 2,306 | USD 2.64 | USD 6,088 | SEC 申报 ↗ |
| 2026-09-14 | Otero Jose Manuel | 奖励/授予 (A) | Common Stock | 2,110 | USD 2.64 | USD 5,570 | SEC 申报 ↗ |
| 2026-09-14 | Bhalla Narinder Pal | 奖励/授予 (A) | Common Stock | 2,714 | USD 3.58 | USD 9,716 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Townsend Richard Nolan | 奖励/授予 (A) | Common Stock | 2,306 | USD 2.64 | USD 6,088 | SEC 申报 ↗ |
| 2026-09-14 | Otero Jose Manuel | 奖励/授予 (A) | Common Stock | 2,110 | USD 2.64 | USD 5,570 | SEC 申报 ↗ |
| 2026-09-14 | Bhalla Narinder Pal | 奖励/授予 (A) | Common Stock | 2,714 | USD 3.58 | USD 9,716 | SEC 申报 ↗ |
| 2026-08-18 | Townsend Richard Nolan | 卖出 (S) | Common Stock | 3,345 | USD 4.95 | USD 16,558 | SEC 申报 ↗ |
| 2026-08-18 | Tamayo Louis Edward | 卖出 (S) | Common Stock | 4,117 | USD 4.91 | USD 20,214 | SEC 申报 ↗ |
| 2026-08-18 | Otero Jose Manuel | 卖出 (S) | Common Stock | 1,304 | USD 4.96 | USD 6,468 | SEC 申报 ↗ |
| 2026-07-01 | Townsend Richard Nolan | 卖出 (S) | Common Stock | 25,947 | USD 4.48 | USD 116,243 | SEC 申报 ↗ |
| 2026-07-01 | Tamayo Louis Edward | 卖出 (S) | Common Stock | 4,641 | USD 4.49 | USD 20,838 | SEC 申报 ↗ |
| 2026-07-01 | Otero Jose Manuel | 卖出 (S) | Common Stock | 4,666 | USD 4.48 | USD 20,904 | SEC 申报 ↗ |
| 2026-07-01 | Bhalla Narinder Pal | 卖出 (S) | Common Stock | 22,306 | USD 4.42 | USD 98,593 | SEC 申报 ↗ |
| 2026-06-29 | Townsend Richard Nolan | 奖励/授予 (A) | Common Stock | 67,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-29 | Tamayo Louis Edward | 奖励/授予 (A) | Common Stock | 12,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-29 | Otero Jose Manuel | 奖励/授予 (A) | Common Stock | 12,060 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-29 | Bhalla Narinder Pal | 奖励/授予 (A) | Common Stock | 55,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Townsend Richard Nolan | 卖出 (S) | Common Stock | 3,342 | USD 5.06 | USD 16,911 | SEC 申报 ↗ |
| 2026-05-18 | Otero Jose Manuel | 卖出 (S) | Common Stock | 1,302 | USD 5.07 | USD 6,601 | SEC 申报 ↗ |
| 2026-04-06 | Townsend Richard Nolan | 卖出 (S) | Common Stock | 55,000 | USD 5.69 | USD 312,950 | SEC 申报 ↗ |
| 2026-03-13 | Townsend Richard Nolan | 奖励/授予 (A) | Common Stock | 2,623 | USD 2.64 | USD 6,925 | SEC 申报 ↗ |
| 2026-03-13 | Otero Jose Manuel | 奖励/授予 (A) | Common Stock | 5,930 | USD 2.64 | USD 15,655 | SEC 申报 ↗ |
| 2026-02-18 | Townsend Richard Nolan | 卖出 (S) | Common Stock | 10,173 | USD 6.38 | USD 64,904 | SEC 申报 ↗ |
| 2026-02-18 | Otero Jose Manuel | 卖出 (S) | Common Stock | 3,016 | USD 6.40 | USD 19,302 | SEC 申报 ↗ |
| 2026-02-13 | Bhalla Narinder Pal | 奖励/授予 (A) | Common Stock | 49,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Townsend Richard Nolan | 奖励/授予 (A) | Common Stock | 161,665 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Tamayo Louis Edward | 奖励/授予 (A) | Common Stock | 44,665 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Otero Jose Manuel | 奖励/授予 (A) | Common Stock | 65,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-18 | Otero Jose Manuel | 卖出 (S) | Common Stock | 721 | USD 9.27 | USD 6,684 | SEC 申报 ↗ |
| 2025-11-18 | Townsend Richard Nolan | 卖出 (S) | Common Stock | 1,127 | USD 9.27 | USD 10,447 | SEC 申报 ↗ |
| 2025-11-18 | See Tai Sandi | 卖出 (S) | Common Stock | 386 | USD 9.27 | USD 3,578 | SEC 申报 ↗ |
| 2025-11-18 | Robertson Jenny | 卖出 (S) | Common Stock | 549 | USD 9.27 | USD 5,089 | SEC 申报 ↗ |
| 2025-11-18 | Adler Eric | 卖出 (S) | Common Stock | 615 | USD 9.27 | USD 5,701 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | LXEO |
| CIK | 0001907108 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 107 transaction lines from 2023-11-07 to 2026-09-14 4 P purchase lines · 54 S sale lines · 49 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.